Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA ...

In a phase 3 trial, izalontamab brengitecan shows superiority to chemotherapy in previously treated esophageal squamous cell carcinoma, but questions remain about generalizability outside China.

For many years, the focus of cancer treatment has been to kill or destroy cancer cells with chemotherapy and radiation. But ...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has unveiled new preclinical data suggesting its lead cancer therapy HMBD-002 ...

A multicenter, open label, phase 3 randomized controlled study has shown that the innovative bispecific antibody, zanidatamab ...

Studies released in recent weeks are fueling optimism — and fresh questions — about GLP-1 drugs' potential role in cancer ...

For patients with high-risk resected melanoma, adding the mRNA vaccine intismeran to pembrolizumab continued to stave off recurrence and distant metastases at 5 years.

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally ...

A new study in Nature Cancer found that montelukast, a common asthma drug, blocks a molecule called CysLTR1 that tumours use ...

New findings from the randomized phase 3 ASCENT-04 trial reinforce prior research that first-line sacituzumab govitecan plus ...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

(NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the ...